Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 7/20 | 0.39 |
| ▸ | NPY1R | P25929 | 5/20 | 0.39 |
| ▸ | NPY2R | P49146 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476574 | 1.00 | DPP7 (0.46) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL2117664 | 1.00 | DPP7 (0.46) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL30259956 | 0.95 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL29630393 | 0.94 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL29350570 | 0.94 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL7996638 | 0.94 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL7996643 | 0.94 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Aspartic Acid SCHEMBL28181767 | 0.92 | DPP7 (0.40) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Arginine SCHEMBL8437780 | 0.89 | GSR (0.51) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL3505407 | 0.89 | NPY4R (0.48) | DPP7NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | claimed |
| CN-118660707-A | Supermolecule self-assembly system | 北京睿创康泰医药研究院有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-115803442-A | Method for preparing guanidinoacetic acid by fermentation | 赢创运营有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | claimed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | claimed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | claimed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | claimed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-0677061-B1 | POLYPEPTIDES AND ANTI-HIV AGENTS PREPARED THEREFROM | SEIKAGAKU KOGYO CO LTD (JP) | 1999-03-03 | — | — | EP | claimed |
| US-5776899-A | Polypeptide and anti-HIV agent prepared therefrom | SEIKAGAKU CORPORATION (JP) | 1998-07-07 | — | — | US | claimed |
| CN-1038841-C | Polypeptide and anti-hiv agent prepared therefrom | SEIKAGAKU CO (JP) | 1998-06-24 | — | — | CN | claimed |
| US-5627035-A | Peptides that block human immunodeficiency virus and methods of use thereof | SYNTELLO VACCINE DEVELOPMENT AB (SE) | 1997-05-06 | — | — | US | claimed |
| CN-1116427-A | Novel polypeptide and anti-HIV agent prepared from the same | SEIKAGAKU KOGYO CO LTD (JP) | 1996-02-07 | — | — | CN | claimed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | claimed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | claimed |
| EP-0545991-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE, Anders (SE) | 1993-06-16 | — | — | EP | claimed |
| WO-1992003147-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | SYNTELLO VACCIN DEVELOPMENT KB (SE) | 1992-03-05 | — | — | WO | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| JP-2023849-A | — | — | None | — | — | JP | disclosed |
| JP-7330573-A | — | — | None | — | — | JP | disclosed |
| JP-7330572-A | — | — | None | — | — | JP | disclosed |
| WO-2026107381-A1 | DNA POLYMERASE THETA INHIBITORS, COMPOSITIONS THEREOF, COMPOSITIONS FURTHER COMPRISING A DNA DEPENDENT PROTEIN KINASE, AND USES OF BOTH IN GENE EDITING FIELD | JUNO THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122045749-A | Method for identifying key flavor substances of rice based on materially group science and machine learning | 华中农业大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | disclosed |
| US-12497644-B2 | Subtilisin variants and their use | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-16 | — | — | US | disclosed |
| CN-120193029-A | Method for synthesizing chiral 2, 6-dimethyl-1-aminoindene serving as pesticide intermediate | 江苏扬农化工股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| CN-119033924-B | Development and application of porcine infectious pleuropneumonia subunit vaccine | 吉林大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-119432787-A | 7 Beta hydroxysteroid dehydrogenase mutant and application thereof in preparation of UDCA | 湖北共同甾体药物研究院有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119040304-A | Xylanase, encoding gene and application thereof | 江西省农业科学院畜牧兽医研究所 | 2024-11-29 | — | — | CN | disclosed |
| CN-118955736-A | FVIIl-apoptin recombinant protein for targeted specificity induction of apoptosis of solid tumor cells, and preparation method and application thereof | 沈阳金石生物制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240342080-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HUMAN BLOOD PROTEIN VITRONECTIN | Sanford Burnham Prebys Medical Discovery Institute | 2024-10-17 | — | — | US | disclosed |
| CN-118660707-A | Supermolecule self-assembly system | 北京睿创康泰医药研究院有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118251497-A | Lipid compositions comprising peptide-lipid conjugates | 阿克丘勒斯治疗公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118063573-A | Arginine-specific transcription regulatory factor mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2024-05-24 | — | — | CN | disclosed |
| EP-4370150-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | Intervet International B.V. (NL) | 2024-05-22 | — | — | EP | disclosed |
| CN-117264047-B | Recombinant III type humanized collagen amino acid sequence and preparation method and application thereof | 南京巴凯星生物科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-117659184-A | Polyclonal antibody of Lawsonia intracellularis LI0004 protein, and preparation method and application thereof | 武汉轻工大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-117089572-A | Low off-target base editor and construction thereof | 中国科学院天津工业生物技术研究所 | 2023-11-21 | — | — | CN | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4146249-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Neuland Laboratories Ltd (IN) | 2023-03-15 | — | — | EP | disclosed |
| CN-115777017-A | Compositions and methods for T cell engineering | 亘喜生物科技（上海）有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115768880-A | Compositions and methods for T cell engineering | 亘喜生物科技（上海）有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023285489-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | INTERVET INTERNATIONAL B.V. (NL) | 2023-01-19 | — | — | WO | disclosed |
| CN-115361912-A | Method and apparatus for in situ formation of a nerve cap with quick release | 图拉维治疗股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115044652-A | Nucleic acid detection kit based on CRISPR/Cas12a system and up-conversion luminescent particle immunochromatography and application | 中国人民解放军军事科学院军事医学研究院 | 2022-09-13 | — | — | CN | disclosed |
| CN-112521504-B | Anti-human EGFR nano antibody and application thereof | 暨南大学 | 2022-08-16 | — | — | CN | disclosed |
| CN-112552402-B | Anti-human EGFR nano antibody and application | 暨南大学 | 2022-08-12 | — | — | CN | disclosed |
| CN-112457405-B | Anti-human EGFR nano antibody and application | 暨南大学 | 2022-08-12 | — | — | CN | disclosed |
| CN-112457404-B | Anti-human EGFR nano antibody and application | 暨南大学 | 2022-08-12 | — | — | CN | disclosed |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | ENZENE BIOSCIENCES LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
| CN-113544270-A | Nanocapsules for delivery of cell modulators | 美国杰特贝林生物制品有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| CN-106795142-A | Stereochemically enriched compositions for delivery of nucleic acids | 夏尔人类遗传性治疗公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106659731-A | Topical compositions and methods for treating wounds | 夏尔人类遗传性治疗公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| EP-3011961-A1 | 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation | Biokine Therapeutics LTD. (IL) | 2016-04-27 | — | — | EP | disclosed |
| EP-2942059-A1 | 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Biokine Therapeutics LTD. (IL) | 2015-11-11 | — | — | EP | disclosed |
| US-9034814-B2 | CXCR4 antagonists for wound healing and re-epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2015-05-19 | — | — | US | disclosed |
| US-20150125549-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2015-05-07 | — | — | US | disclosed |
| EP-2759302-A2 | 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour | Biokine Therapeutics LTD. (IL) | 2014-07-30 | — | — | EP | disclosed |
| US-8765683-B2 | T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy | BIOKINE THERAPEUTICS LTD. (IL) | 2014-07-01 | — | — | US | disclosed |
| EP-2442822-B1 | PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS | BIOKINE THERAPEUTICS LTD (IL) | 2014-03-05 | — | — | EP | disclosed |
| US-8663651-B2 | T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation | BIOKINE THERAPEUTICS LTD. (IL) | 2014-03-04 | — | — | US | disclosed |
| US-20140030211-A1 | METHODS FOR OBTAINING A THERAPEUTICALLY EFFECTIVE AMOUNT OF HEMATOPOIETIC PRECURSOR CELLS AND LONG TERM ENGRAFTMENT THEREOF | BIOKINE THERAPEUTICS LTD. (IL) | 2014-01-30 | — | — | US | disclosed |
| EP-2663320-A1 | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF NEUROECTODERMAL DERIVED TUMORS AND RETINOBLASTOMA | Biokine Therapeutics Ltd. (IL) | 2013-11-20 | — | — | EP | disclosed |
| US-20130303460-A1 | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF NEUROECTODERMAL DERIVED TUMORS AND RETINOBLASTOMA | BIOKINE THERAPEUTICS LTD. (IL) | 2013-11-14 | — | — | US | disclosed |
| US-8455450-B2 | Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2013-06-04 | — | — | US | disclosed |
| US-8435939-B2 | Polypeptide anti-HIV agent containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2013-05-07 | — | — | US | disclosed |
| EP-1898943-B1 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MED RES SERVICE (IL) | 2012-10-10 | — | — | EP | disclosed |
| US-20120207748-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY | BIOKINE THERAPEUTICS LTD. (IL) | 2012-08-16 | — | — | US | disclosed |
| WO-2012095849-A1 | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF NEUROECTODERMAL DERIVED TUMORS AND RETINOBLASTOMA | BIOKINE THERAPEUTICS LTD. (IL) | 2012-07-19 | — | — | WO | disclosed |
| CN-102481332-A | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD | 2012-05-30 | — | — | CN | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| EP-2442822-A2 | PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS | Biokine Therapeutics Ltd. (IL) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094907-A1 | PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS | BIOKINE THERAPEUTICS LTD. (IL) | 2012-04-19 | — | — | US | disclosed |
| WO-2010146578-A2 | PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS | BIOKINE THERAPEUTICS LTD. (IL) | 2010-12-23 | — | — | WO | disclosed |
| US-20100222256-A1 | Novel polypeptide anti-HIV agent containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2010-09-02 | — | — | US | disclosed |
| US-20100184694-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY | BIOKINE THERAPEUTICS LTD. (IL) | 2010-07-22 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100166715-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | BIOKINE THERAPEUTICS LTD. (IL) | 2010-07-01 | — | — | US | disclosed |
| US-20100143334-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | BIOKINE THERAPEUTICS LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | disclosed |
| US-20100047762-A1 | METHOD TO MONITOR DRUG EFFICACY IN DIABETIC PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-02-25 | — | — | US | disclosed |
| US-7595298-B2 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2009-09-29 | — | — | US | disclosed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | disclosed |
| US-20060264605-A1 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2006-11-23 | — | — | US | disclosed |
| US-7138488-B2 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2006-11-21 | — | — | US | disclosed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | disclosed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6060451-A | CARDIOVASCULAR DISORDERS, ANTICARCINOGENIC, ANTIMETASTASIS, AND ANTITUMOR AGENTS | THE NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2000-05-09 | — | — | US | disclosed |
| EP-0624199-B1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS INC (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0677061-B1 | POLYPEPTIDES AND ANTI-HIV AGENTS PREPARED THEREFROM | SEIKAGAKU KOGYO CO LTD (JP) | 1999-03-03 | — | — | EP | disclosed |
| EP-0677061-B1 | POLYPEPTIDES AND ANTI-HIV AGENTS PREPARED THEREFROM | SEIKAGAKU KOGYO CO LTD (JP) | 1999-03-03 | — | — | EP | disclosed |
| EP-0885186-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| US-5776899-A | Polypeptide and anti-HIV agent prepared therefrom | SEIKAGAKU CORPORATION (JP) | 1998-07-07 | — | — | US | disclosed |
| CN-1038841-C | Polypeptide and anti-hiv agent prepared therefrom | SEIKAGAKU CO (JP) | 1998-06-24 | — | — | CN | disclosed |
| CN-1038841-C | Polypeptide and anti-hiv agent prepared therefrom | SEIKAGAKU CO (JP) | 1998-06-24 | — | — | CN | disclosed |
| EP-0536177-B1 | THROMBIN INHIBITORS BASED ON THE AMINO ACID SEQUENCE OF HIRUDIN | CA NAT RESEARCH COUNCIL (CA) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997019911-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
| US-5627035-A | Peptides that block human immunodeficiency virus and methods of use thereof | SYNTELLO VACCINE DEVELOPMENT AB (SE) | 1997-05-06 | — | — | US | disclosed |
| US-5527692-A | COMPRISING ACTIVATED RECOMBINANT GLA-DOMAINLESS PROTHROMBIN, WHICH IS CLEAVABLE TO THROMBIN | ZYMOGENETICS, INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5502034-A | EXPRESSION OF THROMBIN PRECURSOR IN HOST CELL, TREATMENT OF BLEEDING DISORDERS | ZYMOGENETICS, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| CN-1116427-A | Novel polypeptide and anti-HIV agent prepared from the same | SEIKAGAKU KOGYO CO LTD (JP) | 1996-02-07 | — | — | CN | disclosed |
| JP-H07330572-A | COSMETIC FOR SOFTENING SKIN | KAO CORP | 1995-12-19 | — | — | JP | disclosed |
| JP-H07330573-A | COSMETIC FOR SOFTENING SKIN | OSAKA YAKUHIN KENKYUSHO:KK | 1995-12-19 | — | — | JP | disclosed |
| US-5476777-A | DNA construct directing expression of thrombin precursor, including transcriptional promoter, DNA segment encoding gla-domainless prothrombin, transcriptional terminator | ZYMOGENETICS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
| EP-0680469-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1995-11-08 | — | — | EP | disclosed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | disclosed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | disclosed |
| EP-0624199-A1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS, INC. (US) | 1994-11-17 | — | — | EP | disclosed |
| WO-1994017035-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1994-08-04 | — | — | WO | disclosed |
| WO-1993013208-A1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| EP-0545991-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE, Anders (SE) | 1993-06-16 | — | — | EP | disclosed |
| EP-0536177-A1 | THROMBIN INHIBITORS BASED ON THE AMINO ACID SEQUENCE OF HIRUDIN | MAJESTY (HER) IN RIGHT OF CANADA as represented by THE NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1993-04-14 | — | — | EP | disclosed |
| WO-1992003147-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | SYNTELLO VACCIN DEVELOPMENT KB (SE) | 1992-03-05 | — | — | WO | disclosed |
| WO-1991019734-A2 | THROMBIN INHIBITORS BASED ON THE AMINO ACID SEQUENCE OF HIRUDIN | MAJESTY (HER) IN RIGHT OF CANADA AS REPRESENTED BY THE NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1991-12-26 | — | — | WO | disclosed |
| JP-H0223849-A | PEPTIDE-CONTAINING NUTRIENT TRANSFUSION SOLUTION COMPOSITION | MORISHITA PHARMACEUT CO LTD | 1990-01-26 | — | — | JP | disclosed |
| US-4645740-A | REACTING WITH AMINO ACIDS, AMIDES, ESTERS, OR THIOESTER | CARLSBERG BIOTECHNOLOGY LTD. A/S (DK) | 1987-02-24 | — | — | US | disclosed |
| EP-0088117-B1 | PROCESS FOR PREPARING HUMAN INSULIN OR B-30 ESTERS THEREOF | NORDISK INSULINLABORATORIUM (DK) | 1986-09-24 | — | — | EP | disclosed |
| US-4601979-A | Process for preparing human insulin or B-30 esters thereof | NORDISK INSULINLABORATORIUM (DK) | 1986-07-22 | — | — | US | disclosed |
| US-4511505-A | THREONINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1985-04-16 | — | — | US | disclosed |
| EP-0085083-B1 | PROCESS FOR THE ENZYMATIC PREPARATION OF HUMAN INSULIN | NORDISK INSULINLABORATORIUM (DK) | 1985-01-23 | — | — | EP | disclosed |
| EP-0045187-B1 | A PROCESS FOR ENZYMATIC REPLACEMENT OF THE B-30 AMINO ACID IN INSULINS | DE FORENEDE BRYGGERIER A/S (DK) | 1984-10-10 | — | — | EP | disclosed |
| WO-1984003107-A1 | A PROCESS FOR THE PREPARATION OF HUMAN INSULIN | NORDISK INSULINLAB (DK) | 1984-08-16 | — | — | WO | disclosed |
| EP-0088117-A1 | PROCESS FOR PREPARING HUMAN INSULIN OR B-30 ESTERS THEREOF. | NORDISK INSULINLAB (DK) | 1983-09-14 | — | — | EP | disclosed |
| US-4401757-A | CONVERTING ANIMAL INSULIN TO DES-B30-INSULIN, REACTING WITH THREONINE | SHIONOGI & CO., LTD. (JP) | 1983-08-30 | — | — | US | disclosed |
| US-4400465-A | FROM ANIMAL INSULIN BY EXCHANGING THE B30 ALANINE WITH THREONINE | SHIONOGI & CO., LTD. (JP) | 1983-08-23 | — | — | US | disclosed |
| EP-0085083-A1 | Process for the enzymatic preparation of human insulin. | NORDISK INSULINLAB (DK) | 1983-08-10 | — | — | EP | disclosed |
| EP-0079362-A1 | A PROCESS FOR THE PREPARATION OF INSULIN DERIVATIVES | NORDISK INSULINLABORATORIUM (DK) | 1983-05-25 | — | — | EP | disclosed |
| WO-1983001074-A1 | ENZYMATIC PREPARATION OF HUMAN INSULIN OR B-30 ESTERS THEREOF | ANDRESEN, FINN, HEDE | 1983-03-31 | — | — | WO | disclosed |
| WO-1983000504-A1 | ENZYMATIC PREPARATION OF HUMAN INSULIN | ANDRESEN, FINN, HEDE | 1983-02-17 | — | — | WO | disclosed |
| WO-1982004069-A1 | A PROCESS FOR THE PREPARATION OF INSULIN DERIVATIVES | ANDRESEN FINN HEDE | 1982-11-25 | — | — | WO | disclosed |
| US-4320197-A | THREONINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1982-03-16 | — | — | US | disclosed |
| US-4320196-A | ENZYMATIC CATALYZED REACTION WITH THREONINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1982-03-16 | — | — | US | disclosed |
| WO-1982000301-A1 | ENZYMATIC REPLACEMENT OF THE B-30 AMINO ACID IN INSULINS | BREDDAM K | 1982-02-04 | — | — | WO | disclosed |
| EP-0045187-A1 | A process for enzymatic replacement of the B-30 amino acid in insulins | DE FORENEDE BRYGGERIER A/S (DK) | 1982-02-03 | — | — | EP | disclosed |
| US-4244865-A | α hydroxy tripeptide substrates | ABBOTT LABORATORIES (US) | 1981-01-13 | — | — | US | disclosed |
| EP-0017938-A1 | Process for preparing a B30-threonine insulin | SHIONOGI & CO., LTD. (JP) | 1980-10-29 | — | — | EP | disclosed |
| US-4221706-A | B-ALANYL OR G-AMINOBUTYRYL-PROLYL-ARGINYL-P-NITROANILIDE, FOR QUANTITATIVE MEASUREMENT OF PROTEOLYTIC ENZYMES | ABBOTT LABORATORIES (US) | 1980-09-09 | — | — | US | disclosed |
| US-4219497-A | Chromogenic substrates | ABBOTT LABORATORIES (US) | 1980-08-26 | — | — | US | disclosed |
| US-4217269-A | FOR SPECTROPHOTOMETRIC MEASUREMENT OF PROTEOLYTIC ENZYMES | ABBOTT LABORATORIES (US) | 1980-08-12 | — | — | US | disclosed |
| US-4216142-A | Chromogenic substrates for the proteolytic enzymes | ABBOTT LABORATORIES (US) | 1980-08-05 | — | — | US | disclosed |
| US-4029642-A | CONDENSATION OF DES-B OCTAPEPTIDE WITH A PEPTIDE | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-06-14 | — | — | US | disclosed |
| US-3966701-A | ANTICOAGULANTS | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966701-A | ANTICOAGULANTS | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | CXCR4, CXCL12, CXCR5 | DPP7 1920/4885GNAI3 1817/4885GNAO1 2144/4885 |
| US-20120094907-A1 | PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS | MPL, PDGFA, THPO | DPP7 664/4885GNAI3 2243/4885GNAO1 3698/4885 |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | DPP7 9/4885GNAI3 4480/4885GNAO1 4074/4885 |
| US-20120207748-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY | CXCR4, CXCR5, CXCR1 | DPP7 1618/4885GNAI3 942/4885GNAO1 1051/4885 |
| US-20100143334-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | CXCR5, CXCR4, CXCR1 | DPP7 1142/4885GNAI3 1193/4885GNAO1 1587/4885 |
| US-20140030211-A1 | METHODS FOR OBTAINING A THERAPEUTICALLY EFFECTIVE AMOUNT OF HEMATOPOIETIC PRECURSOR CELLS AND LONG TERM ENGRAFTMENT THEREOF | IL15, THPO, BST2 | DPP7 3566/4885GNAI3 1815/4885GNAO1 3129/4885 |
| US-20130303460-A1 | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF NEUROECTODERMAL DERIVED TUMORS AND RETINOBLASTOMA | RB1, NGLY1, RBBP5 | DPP7 2451/4885GNAI3 1952/4885GNAO1 2675/4885 |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | DPP7 488/4885GNAI3 3305/4885GNAO1 4474/4885 |
| US-20100184694-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY | CXCR4, CXCR5, CXCR1 | DPP7 1618/4885GNAI3 942/4885GNAO1 1051/4885 |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | GLP1R, GIPR, GCGR | DPP7 23/4885GNAI3 600/4885GNAO1 792/4885 |
| US-20150125549-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | NGLY1, VIP, TAP1 | DPP7 613/4885GNAI3 3456/4885GNAO1 4646/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | DPP7 8/4885GNAI3 2364/4885GNAO1 749/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | DPP7 633/4885GNAI3 4884/4885GNAO1 4767/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | DPP7 10/4885GNAI3 716/4885GNAO1 901/4885 |
| US-20100166715-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | CXCR4, CXCL12, CXCR1 | DPP7 1937/4885GNAI3 1026/4885GNAO1 1311/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | DPP7 10/4885GNAI3 4056/4885GNAO1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.